#United States #Johnson & Johnson #Raritan #Bladder Cancer #Erda-iDRS

Promising Phase 1 Results for Erda-iDRS in Bladder Cancer Patients

In a significant development for bladder cancer treatment, Johnson & Johnson (NYSE: JNJ) has announced remarkable outcomes from its Phase 1 clinical trial investigating an experimental drug delivery system called Erda-iDRS. This innovative treatment, aimed at individuals suffering from intermediate-risk non-muscle-invasive bladder cancer (NMIBC), has demonstrated an impressive 89% complete response rate among participants whose tumors exhibit certain fibroblast growth factor receptor (FGFR) alterations.

Study Overview

Presented at the European Association of Urology (EAU) Annual Meeting 2026, the open-label, multicenter study evaluated the safety and effectiveness of Erda-iDRS. The investigational system is designed to release erdafitinib, an oral kinase inhibitor, directly into the bladder over a three-month duration. This localized approach seeks to limit systemic exposure and mitigate the side effects often associated with oral treatments.

As of the study's cut-off date on November 3, 2025, 62 patients with recurrent intermediate-risk NMIBC participated, alongside 26 patients classified as high-risk and having undergone Bacillus Calmette-Guérin (BCG) therapy. Participants were assessed for both safety and response metrics, with a primary focus on tolerability and the incidence of adverse events.

Key Findings

The results indicate that the treatment achieved a complete response rate of 89% within the intermediate-risk cohort. Following the initial treatment cycle, half of the responding patients maintained this complete response for a median duration of 18 months. Notably, in the high-risk group, patients experienced a median recurrence-free survival of 20 months, further supporting the therapeutic potential of this investigational approach.

One of the standout aspects of this trial was the treatment’s favorable safety profile. Most reported adverse events were localized, with hematuria and dysuria being the most common, occurring in 32% and 22% of patients, respectively. Serious adverse events were limited, with a small percentage experiencing grade 3 or higher complications.

Clinical Implications

The promising results from this study are particularly encouraging given that FGFR alterations are prevalent in both intermediate-risk (approximately 70%) and high-risk (around 40%) NMIBC. This highlights the importance of targeting these specific genetic changes in bladder cancer treatment.

Dr. Antoni Vilaseca Cabo, a physician involved in the study, remarked, "Achieving and maintaining a complete response is particularly significant in this setting, where recurrence is common and necessitates repeated surgical interventions." His observations underscore the potential impact of precision medicine in the management of bladder cancer.

Dr. Christopher Cutie, Vice President and Disease Area Leader for bladder cancer at Johnson & Johnson, echoed this sentiment, stating, "The high and durable complete responses demonstrated with Erda-iDRS highlight the opportunity to deliver a targeted therapy to these patients."

Future Directions

Encouraged by these findings, Johnson & Johnson plans to advance Phase 2 and Phase 3 trials for Erda-iDRS in both intermediate and high-risk NMIBC populations. The MoonRISe program comprises various studies designed to explore the efficacy of this targeted approach in diverse clinical settings.

Conclusion

Overall, the Phase 1 study results for Erda-iDRS offer hope for patients battling non-muscle-invasive bladder cancer, potentially heralding a new era of precision-based treatment strategies. As we await further evaluations, this innovative therapy could redefine standard care protocols in bladder cancer management.